Northfield Laboratories

Northfield Laboratories was an American biotechnology company based in Evanston, Illinois, whose principal activity was the research and development of blood substitutes. Founded in 1985, the company operated primarily as a development-stage pharmaceutical and biotechnology business rather than as a diversified commercial healthcare group. Its sole major product was PolyHeme, an experimental hemoglobin-based oxygen carrier intended to transport oxygen through the bloodstream when donated red blood cells were unavailable or could not be administered quickly. PolyHeme was designed for use in emergency medicine, trauma care, and resuscitation. The product sought to address situations in which patients had suffered severe blood loss and required immediate oxygen delivery, but where compatible blood was not yet available. As a hemoglobin-based oxygen carrier, PolyHeme was intended to perform part of the oxygen-transport function normally provided by red blood cells. Its proposed use placed it in a difficult regulatory and clinical category: the treatment was aimed at critically injured patients, many of whom could be unconscious or otherwise unable to provide ordinary informed consent. Northfield's business was centered on advancing PolyHeme through clinical development and seeking regulatory authorization in the United States. The company did not establish a broad marketed product portfolio. Instead, its identity, financing needs, public profile, and eventual fate were closely tied to the clinical and regulatory prospects of this single product. The company had 68 employees as of May 31, 2005, illustrating its relatively small scale compared with established pharmaceutical manufacturers. The clinical development program attracted criticism over aspects of its trial design, particularly the circumstances in which treatment and resuscitation could be provided to patients who were in grave condition and unable to give informed consent. These concerns became part of the wider ethical debate surrounding emergency research and the use of exceptions from standard informed-consent requirements. The controversy was connected not only to the product's risks and benefits but also to the practical and ethical difficulties of testing an emergency blood substitute in severely injured patients. PolyHeme ultimately failed to obtain approval from the U.S. Food and Drug Administration. On May 9, 2009, after the FDA informed the company that the product's risks outweighed its benefits, Northfield Laboratories ceased operations. The company therefore remained a development-stage biotechnology enterprise and did not become a commercial supplier of an approved blood substitute. During its operating period, it incurred reported losses of approximately $220 million. Northfield's legacy is consequently associated with both the promise of hemoglobin-based oxygen carriers for emergency care and the scientific, regulatory, and ethical challenges involved in developing them.

Northfield Laboratories was established in 1985 in the United States as a biotechnology company concentrating on blood substitutes and related emergency-care research. Its operating model was that of a research and development enterprise: rather than selling a portfolio of established medicines, it devoted its resources to advancing a central product candidate through clinical testing and regulatory review. That candidate was PolyHeme, a hemoglobin-based oxygen carrier. The product was developed as an alternative or temporary supplement to donated blood in circumstances involving major blood loss. Conventional transfusion can be difficult during the first stages of trauma care because blood may not be immediately available, blood typing may take time, or the patient may require treatment before a hospital has assembled the necessary supplies. PolyHeme's intended function was to carry oxygen through the circulation using modified hemoglobin, addressing the oxygen-delivery problem without serving as a complete replacement for all functions of blood. The product's development placed Northfield at the intersection of biotechnology, trauma medicine, emergency resuscitation, and clinical ethics. Testing an emergency treatment in severely injured patients presents unusual challenges. Patients may be unconscious, disoriented, or otherwise incapable of providing standard informed consent. The treatment may also need to be administered before conventional alternatives can be arranged. Northfield's trials were consequently criticized over elements of their design and over the ethical implications of conducting research in situations where patients were in grave clinical condition and could not personally authorize participation. Northfield remained a small company. A company description reported 68 employees as of May 31, 2005, and the business continued to depend heavily on the progress of PolyHeme. Because PolyHeme was the company's only product, regulatory setbacks had consequences for the entire enterprise rather than for one division within a larger pharmaceutical organization. The company incurred reported losses of approximately $220 million during its operations, reflecting the long and costly development path for an unapproved biotechnology product. PolyHeme did not receive approval from the U.S. Food and Drug Administration. On May 9, 2009, Northfield announced that it was shutting down after the FDA communicated that the product's risks outweighed its benefits. The closure ended the company's operations and its attempt to commercialize PolyHeme. Northfield Laboratories is therefore remembered as a defunct biotechnology developer whose principal project illustrated both the potential appeal of artificial oxygen carriers in trauma medicine and the substantial clinical, regulatory, and ethical barriers facing such products.

• 2009

  Operations cease after FDA assessment

  [1]Northfield Laboratoriesen.wikipedia.org

  On May 9, 2009, the company shut down after the FDA determined that PolyHeme's risks outweighed its benefits.

• 2005

  Company reports 68 employees

  [1]Northfield Laboratoriesen.wikipedia.org

  Northfield was reported to have 68 employees as of May 31, 2005, while continuing development of PolyHeme.

• 1985

  Company founded

  [1]Northfield Laboratoriesen.wikipedia.org

  Northfield Laboratories was founded as a biotechnology research and development company focused on blood substitutes.

Development-stage biotechnology company focused on emergency-care blood substitutes and oxygen-carrying therapies.

• Hemoglobin-based oxygen carrier

  PolyHeme

  PolyHeme was Northfield Laboratories' principal and only major product. It was an experimental hemoglobin-based oxygen carrier intended to transport oxygen through the bloodstream during emergency treatment of severe blood loss. The product was conceived for trauma and resuscitation settings in which donated blood might not be immediately available. Its development involved clinical research in critically injured patients, creating special questions about emergency consent and trial design. PolyHeme never received FDA approval, and the company discontinued operations after the FDA concluded that its risks outweighed its benefits.

• Ethical criticism of PolyHeme clinical trials

  Northfield's clinical-trial program was criticized for design elements involving emergency treatment of patients in grave condition who might be unable to provide informed consent. The criticism reflected broader concerns about emergency research, the use of consent exceptions, and the balance between potential benefit and risk when testing a blood substitute during trauma care.

  Source

Read more

• 2009

  Company shuts down after FDA rejects risk-benefit profileStrategy

  Background

  Northfield's business depended on PolyHeme, which had not received FDA approval. The FDA informed the company that the product's risks outweighed its benefits.

  Action taken

  Northfield Laboratories ceased operations on May 9, 2009.

  Aftermath

  The shutdown ended the company's development and commercialization effort for PolyHeme and left Northfield as a defunct biotechnology company.

  Reported cumulative operating losses. Approximately $220 million in losses during operations (During the company's operating period; exact reporting period not specified in the reference)

  Source

1. 1Northfield Laboratoriesen.wikipedia.org